192316-22-6

Basic information

• Product Name: 1H-Benzimidazole-2-methanol,alpha-methyl-,(alphaS)-(9CI)
• Synonyms: 1H-Benzimidazole-2-methanol,alpha-methyl-,(alphaS)-(9CI);L-(-)-1-(1H-Benzimidazol-2-yl)ethanol;(S)-1-(1H-Benzimidazol-2-yl)ethanol
• CAS NO: 192316-22-6
• Molecular Formula: C₉H₁₀N₂O
• Molecular Weight: 162.19
• Product Categories: BENZIMIDAZOLE
• Mol File: 192316-22-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 174-176 °C
• Boiling Point: 389.2±25.0 °C(Predicted)
• Appearance: /
• Density: 1.285
• PKA: 11.58±0.10(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole-2-methanol,alpha-methyl-,(alphaS)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-2-methanol,alpha-methyl-,(alphaS)-(9CI)(192316-22-6)
• EPA Substance Registry System: 1H-Benzimidazole-2-methanol,alpha-methyl-,(alphaS)-(9CI)(192316-22-6)

Safety Data

• Hazardous Substances Data: 192316-22-6(Hazardous Substances Data)

Usage

Structure

Bicyclic heterocyclic compound
The compound has a bicyclic structure consisting of a benzene ring fused to an imidazole ring.

Derivative

Benzimidazole
1H-Benzimidazole-2-methanol, alpha-methyl-,(alphaS)-(9CI) is a derivative of the parent compound benzimidazole.

Alpha-methyl group

Presence of a methyl group attached to the alpha carbon of the benzimidazole ring
The alpha-methyl group is a specific structural feature of this compound.

Stereoisomer

alphaS
The compound is classified as an alphaS stereoisomer, which refers to the spatial arrangement of the alpha-methyl group in relation to the other atoms in the molecule.

Potential Applications

Pharmaceuticals, agrochemicals, or materials science
As a derivative of benzimidazole, the compound may have applications in various fields, although its specific properties and uses have not been widely documented.

Chirality

The compound exhibits chirality due to the presence of the alphaS stereoisomer designation.

Solubility

Not explicitly mentioned in the material, but as a heterocyclic compound, it may have varying solubility in different solvents (e.g., polar aprotic solvents like DMSO or protic solvents like methanol).

Upstream product

• 79-33-4 L-Lactic acid 
• 95-54-5 1,2-diamino-benzene 
• 108-05-4 vinyl acetate 
• 16414-04-3 1-benzimidazol-2-ylethanol 

Downstream Products

• 2849-93-6 2-benzimidazolecarboxylic acid 
• 170031-70-6 2-(2-acetyl-1H-benzimidazol-1-yl)-1-phenylethanone 

Relevant articles and documents

Achievement of Bulky Homochirality in Zeolitic Imidazolate-Related Frameworks

Before this work, adding chiral C centers into zeolitic imidazolate frameworks (ZIFs) has never been realized. Presented here are the first examples on achieving bulky homochirality in ZIF systems, and three homochiral zeolitic imidazolate-related frameworks with sodalite and dia topologies are successfully synthesized by employing enantiopure imidazolate derivatives. The results open a new blueprint on the synthetic design of homochiral ZIFs for future applications.

Syntheses, Crystal Structures, and Spectral Characterization of Six Novel Benzimidazolyl Substituted Triaryltriazoles

Six new benzimidazolyl substituted triaryltriazoles, 3-(2-pyridyl)-4-(p-R-phenyl)-5-(2-benzimidazolyl)-1,2,4-triazoles (L1: R?=?OCH3; L2: R?=?CH3; L3: R?=?H; L4: R?=?Br; L5: R?=?Cl; L6: R?=?F) were successfully synthesized. Yield of L1–6 is in the range from 61 to 76%. The compounds L1–6 were characterized by UV–vis, FTIR, 1H-NMR, ESI-MS spectra, and elemental analysis. Additionally, the absolute configurations of L1–5 were determined by single crystal X-ray crystallography.

Carbamate compositions and methods fo rmodulating the activity of the CHK1 enzyme

Described herein are carbamate compounds. Such compounds are capable of modulating the activity of a checkpoint kinase, and described herein are methods for utilizing such modulation to treat cell proliferative disorders. Also described are pharmaceutical